Progyny vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Progyny is a fertility and family building benefits management company providing employer-sponsored fertility coverage that improves outcomes and reduces total fertility spend.
About
Progyny is a publicly traded fertility benefits management company founded in 2008 that has become the leading provider of employer-sponsored fertility benefits in the United States. The company manages fertility coverage for self-insured employers, providing access to a national network of top-tier fertility clinics, a proprietary Smart Cycle benefits design that bundles all medically necessary components of a treatment cycle, and dedicated patient care advocates who guide employees through fertility treatment. Progyny went public on Nasdaq in 2019 under the ticker PGNY and serves over 430 employers covering over 6 million lives including many Fortune 500 companies. The company has published clinical outcomes data demonstrating higher live birth rates, lower multiple birth rates, and lower NICU costs compared to traditional indemnity fertility coverage, translating into healthcare cost savings that offset the benefit cost for employers. Progyny's Smart Cycle design bundles medications, lab tests, and procedures into a single benefit unit that eliminates the piecemeal authorization challenges of traditional insurance coverage. The company competes with Carrot Fertility and Kindbody in the employer fertility benefits market.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.